TY - JOUR T1 - Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma JF - Anticancer Research JO - Anticancer Res SP - 527 LP - 532 DO - 10.21873/anticanres.14804 VL - 41 IS - 1 AU - YASUYOSHI SATO AU - KENJI NAKANO AU - NAOKI FUKUDA AU - XIAOFEI WANG AU - TETSUYA URASAKI AU - AKIHIRO OHMOTO AU - MAYU YUNOKAWA AU - MAKIKO ONO AU - JUNICHI TOMOMATSU AU - KEIKO HAYAKAWA AU - YUKI FUNAUCHI AU - TAISUKE TANIZAWA AU - KEISUKE AE AU - SEIICHI MATSUMOTO AU - SHUNJI TAKAHASHI Y1 - 2021/01/01 UR - http://ar.iiarjournals.org/content/41/1/527.abstract N2 - Background: Eribulin is widely used for the treatment of breast cancer and soft-tissue sarcoma (STS). Previous studies identified the pre-treatment absolute lymphocyte count, baseline neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein concentration as potential prognostic markers in patients with breast cancer treated with eribulin. However, prognostic factors for eribulin treatment in patients with STS have not been identified. Patients and Methods: This was a retrospective analysis of data collected prospectively from 53 patients who were treated with eribulin for recurrent or metastatic STS between March 2016 and August 2019. Univariate and multivariate analyses were performed to determine the predictive factors of durable clinical benefit, progression-free survival, and overall survival. Results: L-Sarcoma histology [hazard ratio (HR)=28.20, 95% confidence intervaI (CI)=1.67-476.00; p=0.021] and pre-treatment NLR <3.0 (HR=9.96, 95% CI=1.28-77.7; p=0.028) were independent factors predictive of durable clinical benefit. In addition, pre-treatment NLR <3.0 (HR=0.34, 95% CI=0.16-0.74; p=0.0059) and male sex (HR=0.23, 95% CI=0.10-0.52; p<0.001) were independent factors predictive of better progression-free survival. Conclusion: This retrospective study found that baseline NLR predicts the efficacy of eribulin for STS. ER -